MedTrace Logo

Melatonin Cream Against Acute Radiation Dermatitis in Patients With Early Breast Cancer

NCT03716583 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2021-09-10

No results posted yet for this study

Summary

The aim of the present randomized double-blinded placebo-controlled clinical trial is to investigate if melatonin can protect against acute radiation dermatitis in patients with early breast cancer receiving radiation therapy, and whether this has an impact on the patients' quality of life.

Conditions

Interventions

DRUG

Melatonin

25 mg

DRUG

Dimethyl Sulfoxide

150 mg

DRUG

Placebos

1 g

Sponsors & Collaborators

  • Dennis Bregner Zetner

    lead OTHER

Principal Investigators

  • Dennis B Zetner, MD · Center for Perioperativ Optimization

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-30
Primary Completion
2021-01-31
Completion
2021-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03716583 on ClinicalTrials.gov